Brain Cancer

David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).

Both oncologists and primary care physicians do not provide adequate care to fully address cancer survivorship needs. Learn about why and solutions for people in their cancer journey.

David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, offers advice for patients who have recently been diagnosed with glioblastoma (GBM).

In early 2015, Zika outbreaks caused widespread panic in many parts of North and South America. However, now researchers are exploring the possibility of putting the virus to good use: fighting glioblastoma multiforme (GBM), the most deadly type of brain cancer.

The Food and Drug Administration approved the first ever biosimilar to treat a variety of cancers.

Every six months, I get an MRI to check for recurrence or growth of my brain tumor. This is one of those times. To prepare for tomorrow, I try to remember not to forgo today.

A phase 2 trial – which is still enrolling patients – is investigating multiple targeted agents for the treatment of patients with glioblastoma (GBM).

Moving with a health problem comes with the logistical challenge of finding resources in a new place which is a task conquered through patience, kindness and a lot of organization.

The designation recognizes that the vaccine, an immunotherapy called SurVaxM, would treat a rare disease, defined as one that affects a patient population of less than 200,000 Americans. However, because it acts on a protein that appears in 80 percent of cancers generally, SurVaxM may have wider applications.

The Defeat GBM Research Collaborative is an effort based around three broad ideas: five years, $10 million and a question.

A 15-year brain tumor survivor offers advice and talks about advances since his diagnosis.

There are a number of treatment methods being explored to treat glioblastoma.

For many with glioblastoma, there’s no clear path after standard therapy, but scientists are exploring an array of new options.

Senator John McCain was diagnosed with an aggressive glioblastoma after going to the Mayo Clinic for a routine exam.

A patient's diet may have a great impact on their brain cancer outcomes, according to a recent review.

Anne Llewellyn knows how to be a good nurse. For nearly 40 years, she took care of others in the Emergency Department and Respiratory Intensive Care. Her perspective of the health care industry changed a bit after she became the patient. Diagnosed with a central nervous system brain tumor in November 2014, Llewellyn had to become her own advocate, along with the help of her husband.

A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.

A drug combination is showing promise in mouse models and may lead to a new treatment option for patients with glioblastoma.

Experts from the Dana-Farber Cancer Institute discuss upcoming advances in the field of brain cancer treatment and research.

While other cancers seem to occur more frequently in people with high blood sugar, that is not the case for brain cancer, according to a recent study.

There are so many ideas of what it is to be strong, but what if strength lies in being honest, being vulnerable and being ourselves?

Learn about National Brain Tumor Awareness Month, featuring clear brain tumor facts and the need for brain tumor research, from a 19-year brain tumor survivor.

Glioblastomas are difficult to treat, but researchers are hopeful that clinical trials will lead to new developments.

Malignant tumors of the brain or spinal cord represent about 1 percent of all cancers. Michael Feuerstein, Ph.D., M.P.H., is among that small percentage.

Patients with glioblastoma multiforme (GBM) saw a 37 percent reduced risk of death and increased overall survival (OS) when treated with tumor treating fields (TTFields), according to a landmark analysis of the findings from the EF-14 trial.